JP2005530705A - 糖尿病および他の疾患を治療するための複素環アミド誘導体 - Google Patents
糖尿病および他の疾患を治療するための複素環アミド誘導体 Download PDFInfo
- Publication number
- JP2005530705A JP2005530705A JP2003574198A JP2003574198A JP2005530705A JP 2005530705 A JP2005530705 A JP 2005530705A JP 2003574198 A JP2003574198 A JP 2003574198A JP 2003574198 A JP2003574198 A JP 2003574198A JP 2005530705 A JP2005530705 A JP 2005530705A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- carbon atoms
- oxo
- alkyl
- trimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 49
- -1 Heterocyclic amide Chemical class 0.000 title claims description 188
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 30
- 201000010099 disease Diseases 0.000 title abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 266
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 91
- 150000003839 salts Chemical class 0.000 claims abstract description 48
- 229910052796 boron Inorganic materials 0.000 claims abstract description 36
- 150000001408 amides Chemical group 0.000 claims abstract description 33
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 33
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 29
- 230000037356 lipid metabolism Effects 0.000 claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 26
- 230000023852 carbohydrate metabolic process Effects 0.000 claims abstract description 23
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 17
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 17
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims abstract description 16
- 201000011510 cancer Diseases 0.000 claims abstract description 15
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 14
- KIWUVOGUEXMXSV-UHFFFAOYSA-N rhodanine Chemical compound O=C1CSC(=S)N1 KIWUVOGUEXMXSV-UHFFFAOYSA-N 0.000 claims abstract description 8
- UGWULZWUXSCWPX-UHFFFAOYSA-N 2-sulfanylideneimidazolidin-4-one Chemical group O=C1CNC(=S)N1 UGWULZWUXSCWPX-UHFFFAOYSA-N 0.000 claims abstract description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 103
- 125000004432 carbon atom Chemical group C* 0.000 claims description 102
- 150000003254 radicals Chemical class 0.000 claims description 77
- 125000000217 alkyl group Chemical group 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 69
- 125000001424 substituent group Chemical group 0.000 claims description 61
- 239000001257 hydrogen Substances 0.000 claims description 58
- 125000001072 heteroaryl group Chemical group 0.000 claims description 49
- 125000003118 aryl group Chemical group 0.000 claims description 46
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 46
- 229910052736 halogen Inorganic materials 0.000 claims description 45
- 150000002367 halogens Chemical class 0.000 claims description 45
- 241000699670 Mus sp. Species 0.000 claims description 37
- 241001465754 Metazoa Species 0.000 claims description 36
- 210000002966 serum Anatomy 0.000 claims description 36
- 125000003545 alkoxy group Chemical group 0.000 claims description 33
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 32
- 239000008103 glucose Substances 0.000 claims description 32
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 29
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 27
- 230000004069 differentiation Effects 0.000 claims description 25
- 150000002632 lipids Chemical class 0.000 claims description 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 22
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 20
- 125000004429 atom Chemical group 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 19
- 125000003107 substituted aryl group Chemical group 0.000 claims description 19
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 18
- 125000001188 haloalkyl group Chemical group 0.000 claims description 18
- 239000002243 precursor Substances 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 125000004423 acyloxy group Chemical group 0.000 claims description 16
- 238000005859 coupling reaction Methods 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 15
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims description 14
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 13
- 210000000229 preadipocyte Anatomy 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 238000010168 coupling process Methods 0.000 claims description 11
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 10
- 150000001768 cations Chemical class 0.000 claims description 10
- 230000008878 coupling Effects 0.000 claims description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 235000009200 high fat diet Nutrition 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- HWJYWTWTNWGEPW-UHFFFAOYSA-N 5-[[3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O HWJYWTWTNWGEPW-UHFFFAOYSA-N 0.000 claims description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 4
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229910052744 lithium Inorganic materials 0.000 claims description 4
- TUMQVWIXFYQMPE-UHFFFAOYSA-N 5-[[3-(1,4,4,6-tetramethyl-2-oxo-3h-quinolin-7-yl)-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(C)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O TUMQVWIXFYQMPE-UHFFFAOYSA-N 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 3
- 238000009825 accumulation Methods 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 3
- 229960004919 procaine Drugs 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- IGHXENSMRWDRKA-UHFFFAOYSA-N 5-[[2,5-difluoro-4-methoxy-3-(1,4,4,6-tetramethyl-2-oxo-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound FC1=C(C=2C(=CC=3C(C)(C)CC(=O)N(C)C=3C=2)C)C(OC)=C(F)C=C1C=C1SC(=O)NC1=O IGHXENSMRWDRKA-UHFFFAOYSA-N 0.000 claims description 2
- GQNUPWWBBITQJA-UHFFFAOYSA-N 5-[[2-fluoro-4-methoxy-3-(1,4,4,6-tetramethyl-2-oxo-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound FC1=C(C=2C(=CC=3C(C)(C)CC(=O)N(C)C=3C=2)C)C(OC)=CC=C1C=C1SC(=O)NC1=O GQNUPWWBBITQJA-UHFFFAOYSA-N 0.000 claims description 2
- JUYPRBPAOWLCMA-UHFFFAOYSA-N 5-[[3-(1-benzyl-3,3,5-trimethyl-2-oxoindol-6-yl)-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC(C(C(=O)N2CC=3C=CC=CC=3)(C)C)=C2C=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O JUYPRBPAOWLCMA-UHFFFAOYSA-N 0.000 claims description 2
- ASTKCMGCWSLEGK-UHFFFAOYSA-N 5-[[3-(1-ethyl-3,3,5-trimethyl-2-oxoindol-6-yl)-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CC)C(=O)C(C)(C)C2=CC(C)=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O ASTKCMGCWSLEGK-UHFFFAOYSA-N 0.000 claims description 2
- AJWYRAPTULXKLY-UHFFFAOYSA-N 5-[[3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)-2,5-difluoro-4-methoxyphenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=C(F)C=1)OC)=C(F)C=1C=C1SC(=O)NC1=O AJWYRAPTULXKLY-UHFFFAOYSA-N 0.000 claims description 2
- CXFIOEDVSRZEQP-UHFFFAOYSA-N 5-[[3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)-2-fluoro-4-methoxyphenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)OC)=C(F)C=1C=C1SC(=O)NC1=O CXFIOEDVSRZEQP-UHFFFAOYSA-N 0.000 claims description 2
- BTDIBTFOEQGYNN-UHFFFAOYSA-N 5-[[3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)-5-fluoro-4-methoxyphenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=C(F)C=1)OC)=CC=1C=C1SC(=O)NC1=O BTDIBTFOEQGYNN-UHFFFAOYSA-N 0.000 claims description 2
- OVGKEHDDXLFCLP-UHFFFAOYSA-N 5-[[4-(dimethylamino)-3-(1,4,4,6-tetramethyl-2-oxo-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C(C=2C(=CC=3C(C)(C)CC(=O)N(C)C=3C=2)C)C(N(C)C)=CC=C1C=C1SC(=O)NC1=O OVGKEHDDXLFCLP-UHFFFAOYSA-N 0.000 claims description 2
- GTWRJNHQYADCSI-UHFFFAOYSA-N 5-[[4-(dimethylamino)-3-(1,4,7-trimethyl-2,3-dioxoquinoxalin-6-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C(C=2C(=CC=3N(C)C(=O)C(=O)N(C)C=3C=2)C)C(N(C)C)=CC=C1C=C1SC(=O)NC1=O GTWRJNHQYADCSI-UHFFFAOYSA-N 0.000 claims description 2
- NBTOFQXOPMRLOR-UHFFFAOYSA-N 5-[[4-(dimethylamino)-3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)N(C)C)=CC=1C=C1SC(=O)NC1=O NBTOFQXOPMRLOR-UHFFFAOYSA-N 0.000 claims description 2
- NDSWOANBUNAJAY-UHFFFAOYSA-N 5-[[4-(dimethylamino)-3-(4,4,6-trimethyl-2-oxo-1-propan-2-yl-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(C(C)C)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)N(C)C)=CC=1C=C1SC(=O)NC1=O NDSWOANBUNAJAY-UHFFFAOYSA-N 0.000 claims description 2
- XYWRENBSTJWTMP-UHFFFAOYSA-N 5-[[4-(dimethylamino)-3-(4,4,6-trimethyl-2-oxo-1-propyl-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CCC)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)N(C)C)=CC=1C=C1SC(=O)NC1=O XYWRENBSTJWTMP-UHFFFAOYSA-N 0.000 claims description 2
- FQHFXXCZTRYANX-UHFFFAOYSA-N 5-[[4-(ethylamino)-3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C(C=2C(=CC=3C(C)(C)CC(=O)N(CC)C=3C=2)C)C(NCC)=CC=C1C=C1SC(=O)NC1=O FQHFXXCZTRYANX-UHFFFAOYSA-N 0.000 claims description 2
- RPBRNECKATZCRH-UHFFFAOYSA-N 5-[[4-(trifluoromethoxy)-3-(3,3,5-trimethyl-2-oxo-1-propylindol-6-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CCC)C(=O)C(C)(C)C2=CC(C)=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O RPBRNECKATZCRH-UHFFFAOYSA-N 0.000 claims description 2
- MXULYIDUFRFMCN-UHFFFAOYSA-N 5-[[4-(trifluoromethoxy)-3-(3,3,5-trimethyl-2-oxo-1h-indol-6-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC(C(C(=O)N2)(C)C)=C2C=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O MXULYIDUFRFMCN-UHFFFAOYSA-N 0.000 claims description 2
- RXSDNKZJROLXLW-UHFFFAOYSA-N 5-[[4-(trifluoromethoxy)-3-(4,4,6-trimethyl-2-oxo-1-propan-2-yl-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(C(C)C)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O RXSDNKZJROLXLW-UHFFFAOYSA-N 0.000 claims description 2
- KBJIHTLGARZNBW-UHFFFAOYSA-N 5-[[4-(trifluoromethoxy)-3-(4,4,6-trimethyl-2-oxo-1-propyl-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CCC)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O KBJIHTLGARZNBW-UHFFFAOYSA-N 0.000 claims description 2
- JMABEOVVSGPWJR-UHFFFAOYSA-N 5-[[4-chloro-3-(1,4,4,6-tetramethyl-2-oxo-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(C)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)Cl)=CC=1C=C1SC(=O)NC1=O JMABEOVVSGPWJR-UHFFFAOYSA-N 0.000 claims description 2
- JNBZPXIGSUERNY-UHFFFAOYSA-N 5-[[4-chloro-3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)Cl)=CC=1C=C1SC(=O)NC1=O JNBZPXIGSUERNY-UHFFFAOYSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
- 229940043237 diethanolamine Drugs 0.000 claims description 2
- 229940012017 ethylenediamine Drugs 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 229960003194 meglumine Drugs 0.000 claims description 2
- 235000019371 penicillin G benzathine Nutrition 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 125000002431 aminoalkoxy group Chemical group 0.000 claims 7
- 150000004703 alkoxides Chemical class 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims 1
- 229940006486 zinc cation Drugs 0.000 claims 1
- 208000035475 disorder Diseases 0.000 abstract description 7
- 230000002062 proliferating effect Effects 0.000 abstract description 7
- 150000001720 carbohydrates Chemical class 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 199
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 125
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 99
- 239000000243 solution Substances 0.000 description 84
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 83
- 235000019439 ethyl acetate Nutrition 0.000 description 70
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 68
- 239000000203 mixture Substances 0.000 description 68
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 65
- 239000012267 brine Substances 0.000 description 55
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 55
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 51
- 235000012000 cholesterol Nutrition 0.000 description 40
- 239000011541 reaction mixture Substances 0.000 description 39
- 229910052786 argon Inorganic materials 0.000 description 34
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 31
- 229940125846 compound 25 Drugs 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 30
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- 125000005432 dialkylcarboxamide group Chemical group 0.000 description 27
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 125000005431 alkyl carboxamide group Chemical group 0.000 description 25
- 239000000741 silica gel Substances 0.000 description 24
- 229910002027 silica gel Inorganic materials 0.000 description 24
- 239000000543 intermediate Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 20
- 150000005347 biaryls Chemical group 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 125000000547 substituted alkyl group Chemical group 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 210000001789 adipocyte Anatomy 0.000 description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 16
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 15
- 229910052799 carbon Inorganic materials 0.000 description 15
- 239000010410 layer Substances 0.000 description 15
- 229910000027 potassium carbonate Inorganic materials 0.000 description 15
- 125000005415 substituted alkoxy group Chemical group 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 14
- 229940125782 compound 2 Drugs 0.000 description 14
- 235000005911 diet Nutrition 0.000 description 14
- 230000037213 diet Effects 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- 0 CC1C(C)I(*)INB*1 Chemical compound CC1C(C)I(*)INB*1 0.000 description 12
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 12
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 12
- 229940125961 compound 24 Drugs 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 150000001721 carbon Chemical group 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229910052740 iodine Inorganic materials 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 125000004001 thioalkyl group Chemical group 0.000 description 10
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- PJAKAPWOIDACRK-UHFFFAOYSA-N 7-bromo-4,4,6-trimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=C(Br)C(C)=CC2=C1NC(=O)CC2(C)C PJAKAPWOIDACRK-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229910052794 bromium Inorganic materials 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000008159 sesame oil Substances 0.000 description 9
- 235000011803 sesame oil Nutrition 0.000 description 9
- CNBHOGNVZIMKAQ-UHFFFAOYSA-N 7-bromo-1,4,4,6-tetramethyl-3h-quinolin-2-one Chemical compound CC1=C(Br)C=C2N(C)C(=O)CC(C)(C)C2=C1 CNBHOGNVZIMKAQ-UHFFFAOYSA-N 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 8
- 210000000497 foam cell Anatomy 0.000 description 8
- 230000000977 initiatory effect Effects 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 238000001953 recrystallisation Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 241000283984 Rodentia Species 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 125000003710 aryl alkyl group Chemical group 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- GAFKOXBCANIIRL-UHFFFAOYSA-N 4-(trifluoromethoxy)-3-(3,3,5-trimethyl-2-oxo-1h-indol-6-yl)benzaldehyde Chemical compound CC1=CC(C(C(=O)N2)(C)C)=C2C=C1C1=CC(C=O)=CC=C1OC(F)(F)F GAFKOXBCANIIRL-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 6
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 6
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 6
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 description 5
- SSIVEDPNMAMSDY-UHFFFAOYSA-N 7-bromo-1-ethyl-4,4,6-trimethyl-3h-quinolin-2-one Chemical compound CC1=C(Br)C=C2N(CC)C(=O)CC(C)(C)C2=C1 SSIVEDPNMAMSDY-UHFFFAOYSA-N 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 238000008214 LDL Cholesterol Methods 0.000 description 5
- 238000006069 Suzuki reaction reaction Methods 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- 239000003183 carcinogenic agent Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000009833 condensation Methods 0.000 description 5
- 230000005494 condensation Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 5
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical class CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 5
- SEPKUNXLGWMPHL-UHFFFAOYSA-N quinoxaline-2,3-dione Chemical compound C1=CC=CC2=NC(=O)C(=O)N=C21 SEPKUNXLGWMPHL-UHFFFAOYSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 125000005017 substituted alkenyl group Chemical group 0.000 description 5
- 125000004426 substituted alkynyl group Chemical group 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- DMTYZWDMNXEIDM-UHFFFAOYSA-N (2-formylquinolin-4-yl) trifluoromethanesulfonate Chemical compound C1=CC=C2C(OS(=O)(=O)C(F)(F)F)=CC(C=O)=NC2=C1 DMTYZWDMNXEIDM-UHFFFAOYSA-N 0.000 description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- KZRXNWKQSSTNPU-UHFFFAOYSA-N 2-fluoro-3-iodo-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(F)=C1I KZRXNWKQSSTNPU-UHFFFAOYSA-N 0.000 description 4
- VFXOIGRNGVEWPT-UHFFFAOYSA-N 2-fluoro-4-methoxy-3-(1,4,4,6-tetramethyl-2-oxo-3h-quinolin-7-yl)benzaldehyde Chemical compound COC1=CC=C(C=O)C(F)=C1C(C(=C1)C)=CC2=C1C(C)(C)CC(=O)N2C VFXOIGRNGVEWPT-UHFFFAOYSA-N 0.000 description 4
- HNXJPKMBEAKBRC-UHFFFAOYSA-N 3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)-4-(trifluoromethoxy)benzaldehyde Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C1=CC(C=O)=CC=C1OC(F)(F)F HNXJPKMBEAKBRC-UHFFFAOYSA-N 0.000 description 4
- JUQPMGSSKZAASF-UHFFFAOYSA-N 3-bromo-2,5-difluoro-4-methoxybenzaldehyde Chemical compound COC1=C(F)C=C(C=O)C(F)=C1Br JUQPMGSSKZAASF-UHFFFAOYSA-N 0.000 description 4
- KBFMRPNTVLMTEU-UHFFFAOYSA-N 4-(dimethylamino)-3-(1,4,4,6-tetramethyl-2-oxo-3h-quinolin-7-yl)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1C(C(=C1)C)=CC2=C1C(C)(C)CC(=O)N2C KBFMRPNTVLMTEU-UHFFFAOYSA-N 0.000 description 4
- UMPFFBBYTXNZEM-UHFFFAOYSA-N 4-(trifluoromethoxy)-3-(4,4,6-trimethyl-2-oxo-1-propan-2-yl-3h-quinolin-7-yl)benzaldehyde Chemical compound C1=C2N(C(C)C)C(=O)CC(C)(C)C2=CC(C)=C1C1=CC(C=O)=CC=C1OC(F)(F)F UMPFFBBYTXNZEM-UHFFFAOYSA-N 0.000 description 4
- YUYDUEOSHRCPRR-UHFFFAOYSA-N 4-(trifluoromethoxy)-3-(4,4,6-trimethyl-2-oxo-1-propyl-3h-quinolin-7-yl)benzaldehyde Chemical compound C1=C2N(CCC)C(=O)CC(C)(C)C2=CC(C)=C1C1=CC(C=O)=CC=C1OC(F)(F)F YUYDUEOSHRCPRR-UHFFFAOYSA-N 0.000 description 4
- LSKRWPRFCQDQRI-UHFFFAOYSA-N 4-chloro-3-(1,4,4,6-tetramethyl-2-oxo-3h-quinolin-7-yl)benzaldehyde Chemical compound C1=C2N(C)C(=O)CC(C)(C)C2=CC(C)=C1C1=CC(C=O)=CC=C1Cl LSKRWPRFCQDQRI-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000003178 anti-diabetic effect Effects 0.000 description 4
- 150000001502 aryl halides Chemical class 0.000 description 4
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 4
- 201000008274 breast adenocarcinoma Diseases 0.000 description 4
- 230000000711 cancerogenic effect Effects 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 231100000357 carcinogen Toxicity 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 230000000593 degrading effect Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 150000002391 heterocyclic compounds Chemical class 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- JQRYUMGHOUYJFW-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [Br-].[Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 JQRYUMGHOUYJFW-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 4
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 4
- OQIHDYRMRWEKHE-UHFFFAOYSA-N (3,3,5-trimethyl-2-oxo-1h-indol-6-yl) trifluoromethanesulfonate Chemical compound C1=C(OS(=O)(=O)C(F)(F)F)C(C)=CC2=C1NC(=O)C2(C)C OQIHDYRMRWEKHE-UHFFFAOYSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- ZDYZXDMSXMJOEV-UHFFFAOYSA-N 1,4,6-trimethylquinoxaline-2,3-dione Chemical compound CN1C(=O)C(=O)N(C)C2=CC(C)=CC=C21 ZDYZXDMSXMJOEV-UHFFFAOYSA-N 0.000 description 3
- ARUFMVSDUAMBFY-UHFFFAOYSA-N 1-benzyl-6-hydroxy-3,3,5-trimethylindol-2-one Chemical compound C1=C(O)C(C)=CC(C(C2=O)(C)C)=C1N2CC1=CC=CC=C1 ARUFMVSDUAMBFY-UHFFFAOYSA-N 0.000 description 3
- FXOWNWCPCUXUCM-UHFFFAOYSA-N 1-benzyl-6-methoxy-3,3,5-trimethylindol-2-one Chemical compound O=C1C(C)(C)C=2C=C(C)C(OC)=CC=2N1CC1=CC=CC=C1 FXOWNWCPCUXUCM-UHFFFAOYSA-N 0.000 description 3
- ADHJHCGBDBRJMB-UHFFFAOYSA-N 2,5-difluoro-4-methoxy-3-(1,4,4,6-tetramethyl-2-oxo-3h-quinolin-7-yl)benzaldehyde Chemical compound COC1=C(F)C=C(C=O)C(F)=C1C(C(=C1)C)=CC2=C1C(C)(C)CC(=O)N2C ADHJHCGBDBRJMB-UHFFFAOYSA-N 0.000 description 3
- WGVJMLYQPNCPSD-UHFFFAOYSA-N 2-bromo-5-methoxy-4-methylaniline Chemical compound COC1=CC(N)=C(Br)C=C1C WGVJMLYQPNCPSD-UHFFFAOYSA-N 0.000 description 3
- PZOHUMMUXJAVNV-UHFFFAOYSA-N 3-(1,4,4,6-tetramethyl-2-oxo-3h-quinolin-7-yl)-4-(trifluoromethoxy)benzaldehyde Chemical compound C1=C2N(C)C(=O)CC(C)(C)C2=CC(C)=C1C1=CC(C=O)=CC=C1OC(F)(F)F PZOHUMMUXJAVNV-UHFFFAOYSA-N 0.000 description 3
- GDZJJQKARQQWRS-UHFFFAOYSA-N 3-(1-benzyl-3,3,5-trimethyl-2-oxoindol-6-yl)-4-(trifluoromethoxy)benzaldehyde Chemical compound CC1=CC(C(C(=O)N2CC=3C=CC=CC=3)(C)C)=C2C=C1C1=CC(C=O)=CC=C1OC(F)(F)F GDZJJQKARQQWRS-UHFFFAOYSA-N 0.000 description 3
- VWOYSIGIEVHTRQ-UHFFFAOYSA-N 3-bromo-4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1Br VWOYSIGIEVHTRQ-UHFFFAOYSA-N 0.000 description 3
- XUBRIMJGYHSDAR-UHFFFAOYSA-N 3-bromo-4-(ethylamino)benzaldehyde Chemical compound CCNC1=CC=C(C=O)C=C1Br XUBRIMJGYHSDAR-UHFFFAOYSA-N 0.000 description 3
- AKDABJGHOOCVKX-UHFFFAOYSA-N 3-bromo-4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1Br AKDABJGHOOCVKX-UHFFFAOYSA-N 0.000 description 3
- GRXMMIBZRMKADT-UHFFFAOYSA-N 3-bromo-4-methylaniline Chemical compound CC1=CC=C(N)C=C1Br GRXMMIBZRMKADT-UHFFFAOYSA-N 0.000 description 3
- ONADZNBSLRAJFW-UHFFFAOYSA-N 3-methoxy-4-methylaniline Chemical compound COC1=CC(N)=CC=C1C ONADZNBSLRAJFW-UHFFFAOYSA-N 0.000 description 3
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 3
- KZVSSYOBRMRKAW-UHFFFAOYSA-N 4-(ethylamino)-3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)benzaldehyde Chemical compound CCNC1=CC=C(C=O)C=C1C(C(=C1)C)=CC2=C1C(C)(C)CC(=O)N2CC KZVSSYOBRMRKAW-UHFFFAOYSA-N 0.000 description 3
- HGNFGAFGLAHEDK-UHFFFAOYSA-N 6-bromo-1,4,7-trimethylquinoxaline-2,3-dione Chemical compound CN1C(=O)C(=O)N(C)C2=C1C=C(C)C(Br)=C2 HGNFGAFGLAHEDK-UHFFFAOYSA-N 0.000 description 3
- HOHZZPCLZWZMOM-UHFFFAOYSA-N 6-methyl-1,4-dihydroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=CC(C)=CC=C21 HOHZZPCLZWZMOM-UHFFFAOYSA-N 0.000 description 3
- QBRKQYMAWUFRDT-UHFFFAOYSA-N 7-bromo-4,4,6-trimethyl-1-propyl-3h-quinolin-2-one Chemical compound CC1=C(Br)C=C2N(CCC)C(=O)CC(C)(C)C2=C1 QBRKQYMAWUFRDT-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 239000013626 chemical specie Substances 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- LCSNDSFWVKMJCT-UHFFFAOYSA-N dicyclohexyl-(2-phenylphenyl)phosphane Chemical group C1CCCCC1P(C=1C(=CC=CC=1)C=1C=CC=CC=1)C1CCCCC1 LCSNDSFWVKMJCT-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- XGOQDFJVDHMBKQ-UHFFFAOYSA-N n-(2-bromo-5-methoxy-4-methylphenyl)-2-methylpropanamide Chemical compound COC1=CC(NC(=O)C(C)C)=C(Br)C=C1C XGOQDFJVDHMBKQ-UHFFFAOYSA-N 0.000 description 3
- HZGRQOIWBSRYTI-UHFFFAOYSA-N n-(3-bromo-4-methylphenyl)-3-methylbut-2-enamide Chemical compound CC(C)=CC(=O)NC1=CC=C(C)C(Br)=C1 HZGRQOIWBSRYTI-UHFFFAOYSA-N 0.000 description 3
- YYDMGLLIVHEAFK-UHFFFAOYSA-N n-benzyl-n-(2-bromo-5-methoxy-4-methylphenyl)-2-methylpropanamide Chemical compound C1=C(C)C(OC)=CC(N(CC=2C=CC=CC=2)C(=O)C(C)C)=C1Br YYDMGLLIVHEAFK-UHFFFAOYSA-N 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- USFSBAOIOIIGFJ-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]-3,3,5-trimethylindol-2-one Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=C(C)C=C2C(C)(C)C1=O USFSBAOIOIIGFJ-UHFFFAOYSA-N 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
- XANVIFOBBVAKCY-UHFFFAOYSA-N 1-bromo-2-fluoro-4-methoxybenzene Chemical compound COC1=CC=C(Br)C(F)=C1 XANVIFOBBVAKCY-UHFFFAOYSA-N 0.000 description 2
- RXXNAPLWKYEPLD-UHFFFAOYSA-N 1-ethyl-4,4,6-trimethyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3h-quinolin-2-one Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1B1OC(C)(C)C(C)(C)O1 RXXNAPLWKYEPLD-UHFFFAOYSA-N 0.000 description 2
- FFPHRYLGIPAZBL-UHFFFAOYSA-N 2,5-difluoro-4-hydroxybenzaldehyde Chemical compound OC1=CC(F)=C(C=O)C=C1F FFPHRYLGIPAZBL-UHFFFAOYSA-N 0.000 description 2
- UWEZBKLLMKVIPI-UHFFFAOYSA-N 2,5-dinitrophenol Chemical compound OC1=CC([N+]([O-])=O)=CC=C1[N+]([O-])=O UWEZBKLLMKVIPI-UHFFFAOYSA-N 0.000 description 2
- AHPNFDUORGLKLN-UHFFFAOYSA-N 2-(2-fluoro-3-iodo-4-methoxyphenyl)-1,3-dioxolane Chemical compound FC1=C(I)C(OC)=CC=C1C1OCCO1 AHPNFDUORGLKLN-UHFFFAOYSA-N 0.000 description 2
- NZIRPRNRDXSPAP-UHFFFAOYSA-N 2-(2-fluoro-4-methoxyphenyl)-1,3-dioxolane Chemical compound FC1=CC(OC)=CC=C1C1OCCO1 NZIRPRNRDXSPAP-UHFFFAOYSA-N 0.000 description 2
- UNWQNFJBBWXFBG-UHFFFAOYSA-N 2-fluoro-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(F)=C1 UNWQNFJBBWXFBG-UHFFFAOYSA-N 0.000 description 2
- MRTXCDGHYHYRRK-UHFFFAOYSA-N 3-(1-ethyl-3,3,5-trimethyl-2-oxoindol-6-yl)-4-(trifluoromethoxy)benzaldehyde Chemical compound C1=C2N(CC)C(=O)C(C)(C)C2=CC(C)=C1C1=CC(C=O)=CC=C1OC(F)(F)F MRTXCDGHYHYRRK-UHFFFAOYSA-N 0.000 description 2
- ZEVHLAPHOLQZKE-UHFFFAOYSA-N 3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)-2,5-difluoro-4-methoxybenzaldehyde Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C1=C(F)C(C=O)=CC(F)=C1OC ZEVHLAPHOLQZKE-UHFFFAOYSA-N 0.000 description 2
- LZHLMTIYRMCYPZ-UHFFFAOYSA-N 3-bromo-2,5-difluoro-4-hydroxybenzaldehyde Chemical compound OC1=C(F)C=C(C=O)C(F)=C1Br LZHLMTIYRMCYPZ-UHFFFAOYSA-N 0.000 description 2
- QQSOKNIUOFMGHE-UHFFFAOYSA-N 3-bromo-5-fluoro-4-methoxybenzaldehyde Chemical compound COC1=C(F)C=C(C=O)C=C1Br QQSOKNIUOFMGHE-UHFFFAOYSA-N 0.000 description 2
- PSFYFMXVPVBVNK-UHFFFAOYSA-N 4-(dimethylamino)-3-(1,4,7-trimethyl-2,3-dioxoquinoxalin-6-yl)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1C(C(=C1)C)=CC2=C1N(C)C(=O)C(=O)N2C PSFYFMXVPVBVNK-UHFFFAOYSA-N 0.000 description 2
- VOZPBSXWLDIHGY-UHFFFAOYSA-N 4-(trifluoromethoxy)-3-(3,3,5-trimethyl-2-oxo-1-propylindol-6-yl)benzaldehyde Chemical compound C1=C2N(CCC)C(=O)C(C)(C)C2=CC(C)=C1C1=CC(C=O)=CC=C1OC(F)(F)F VOZPBSXWLDIHGY-UHFFFAOYSA-N 0.000 description 2
- GAYVIWVPLPVDHT-UHFFFAOYSA-N 4-(trifluoromethoxy)-3-(4,4,6-trimethyl-2-oxo-1,3-dihydroquinolin-7-yl)benzaldehyde Chemical compound CC1=CC(C(CC(=O)N2)(C)C)=C2C=C1C1=CC(C=O)=CC=C1OC(F)(F)F GAYVIWVPLPVDHT-UHFFFAOYSA-N 0.000 description 2
- HNXAOZLRMOIOSS-UHFFFAOYSA-N 4-chloro-3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)benzaldehyde Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C1=CC(C=O)=CC=C1Cl HNXAOZLRMOIOSS-UHFFFAOYSA-N 0.000 description 2
- ZCFXFIHRHWRKAY-UHFFFAOYSA-N 5-[[3-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O ZCFXFIHRHWRKAY-UHFFFAOYSA-N 0.000 description 2
- ZMZSNUROGZUHAW-UHFFFAOYSA-N 6-hydroxy-3,3,5-trimethyl-1h-indol-2-one Chemical compound C1=C(O)C(C)=CC2=C1NC(=O)C2(C)C ZMZSNUROGZUHAW-UHFFFAOYSA-N 0.000 description 2
- UODCBMPAVVLWGY-UHFFFAOYSA-N 7-bromo-4,4,6-trimethyl-1-propan-2-yl-3h-quinolin-2-one Chemical compound CC1=C(Br)C=C2N(C(C)C)C(=O)CC(C)(C)C2=C1 UODCBMPAVVLWGY-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- XYWDPYKBIRQXQS-UHFFFAOYSA-N Diisopropyl sulfide Chemical compound CC(C)SC(C)C XYWDPYKBIRQXQS-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000005874 Vilsmeier-Haack formylation reaction Methods 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 150000001491 aromatic compounds Chemical class 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000012455 biphasic mixture Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 208000020450 carbohydrate metabolism disease Diseases 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000012954 diazonium Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- WAMUUPMTZJJGAW-UHFFFAOYSA-N ethyl 4-(trifluoromethylsulfonyl)quinoline-2-carboxylate Chemical compound C1=CC=CC2=NC(C(=O)OCC)=CC(S(=O)(=O)C(F)(F)F)=C21 WAMUUPMTZJJGAW-UHFFFAOYSA-N 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 208000017745 inborn carbohydrate metabolic disease Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 229940047889 isobutyramide Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000021542 oral nutrition Nutrition 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- SFLXUZPXEWWQNH-UHFFFAOYSA-K tetrabutylazanium;tribromide Chemical compound [Br-].[Br-].[Br-].CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC SFLXUZPXEWWQNH-UHFFFAOYSA-K 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 2
- 150000008648 triflates Chemical class 0.000 description 2
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
- 229960001641 troglitazone Drugs 0.000 description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- XUJFBCWEVBWOLI-UHFFFAOYSA-N (1-benzyl-3,3,5-trimethyl-2-oxoindol-6-yl) trifluoromethanesulfonate Chemical compound C1=C(OS(=O)(=O)C(F)(F)F)C(C)=CC(C(C2=O)(C)C)=C1N2CC1=CC=CC=C1 XUJFBCWEVBWOLI-UHFFFAOYSA-N 0.000 description 1
- QYYZXEPEVBXNNA-QGZVFWFLSA-N (1R)-2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound C(C)(=O)N1[C@H](C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)O QYYZXEPEVBXNNA-QGZVFWFLSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical compound CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- WEJGLUQSOATNGR-UHFFFAOYSA-N 1,3,3,4-tetramethyl-4H-quinolin-2-one Chemical compound CC1C(C(N(C2=CC=CC=C12)C)=O)(C)C WEJGLUQSOATNGR-UHFFFAOYSA-N 0.000 description 1
- KHNIBLSPHKTIAE-UHFFFAOYSA-N 1,4,4,6-tetramethyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3h-quinolin-2-one Chemical compound C1=C2N(C)C(=O)CC(C)(C)C2=CC(C)=C1B1OC(C)(C)C(C)(C)O1 KHNIBLSPHKTIAE-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- PZBPKYOVPCNPJY-UHFFFAOYSA-N 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=C)CN1C=NC=C1 PZBPKYOVPCNPJY-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- OKCORFVSTXMMGZ-UHFFFAOYSA-N 1-ethyl-4,4,6-trimethyl-3H-quinolin-2-one Chemical compound CCN1C(=O)CC(C2=C1C=CC(=C2)C)(C)C OKCORFVSTXMMGZ-UHFFFAOYSA-N 0.000 description 1
- MFJNOXOAIFNSBX-UHFFFAOYSA-N 1-fluoro-3-methoxybenzene Chemical compound COC1=CC=CC(F)=C1 MFJNOXOAIFNSBX-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- XFZFJQHXWJIBQV-UHFFFAOYSA-N 2-bromo-1-methyl-4-nitrobenzene Chemical compound CC1=CC=C([N+]([O-])=O)C=C1Br XFZFJQHXWJIBQV-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- WVQGZNRUEVFXKR-UHFFFAOYSA-N 2-methoxy-1-methyl-4-nitrobenzene Chemical compound COC1=CC([N+]([O-])=O)=CC=C1C WVQGZNRUEVFXKR-UHFFFAOYSA-N 0.000 description 1
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- CYKREIUNECUPJV-UHFFFAOYSA-N 3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)-2-fluoro-4-methoxybenzaldehyde Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C1=C(F)C(C=O)=CC=C1OC CYKREIUNECUPJV-UHFFFAOYSA-N 0.000 description 1
- WELPCQAOQVBHOX-UHFFFAOYSA-N 3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)-5-fluoro-4-methoxybenzaldehyde Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C1=CC(C=O)=CC(F)=C1OC WELPCQAOQVBHOX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OCIAOFZMQWTYNX-UHFFFAOYSA-N 3-bromo-4-(trifluoromethoxy)benzaldehyde Chemical compound FC(F)(F)OC1=CC=C(C=O)C=C1Br OCIAOFZMQWTYNX-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- SOQCZBSZZLWDGU-UHFFFAOYSA-N 3-fluoro-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1F SOQCZBSZZLWDGU-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- BDUBTLFQHNYXPC-UHFFFAOYSA-N 3-methylbut-2-enoyl chloride Chemical compound CC(C)=CC(Cl)=O BDUBTLFQHNYXPC-UHFFFAOYSA-N 0.000 description 1
- XQSXUDFDIMWBNI-UHFFFAOYSA-N 4,4,6-trimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=CC(C)=CC=C21 XQSXUDFDIMWBNI-UHFFFAOYSA-N 0.000 description 1
- MNFZZNNFORDXSV-UHFFFAOYSA-N 4-(diethylamino)benzaldehyde Chemical compound CCN(CC)C1=CC=C(C=O)C=C1 MNFZZNNFORDXSV-UHFFFAOYSA-N 0.000 description 1
- XJKFRCMAWABHGE-UHFFFAOYSA-N 4-(dimethylamino)-3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)benzaldehyde Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C1=CC(C=O)=CC=C1N(C)C XJKFRCMAWABHGE-UHFFFAOYSA-N 0.000 description 1
- IGYJWYGFPIMMMM-UHFFFAOYSA-N 4-(dimethylamino)-3-(4,4,6-trimethyl-2-oxo-1-propan-2-yl-3h-quinolin-7-yl)benzaldehyde Chemical compound C1=C2N(C(C)C)C(=O)CC(C)(C)C2=CC(C)=C1C1=CC(C=O)=CC=C1N(C)C IGYJWYGFPIMMMM-UHFFFAOYSA-N 0.000 description 1
- UDCGOFJVJFTADG-UHFFFAOYSA-N 4-(dimethylamino)-3-(4,4,6-trimethyl-2-oxo-1-propyl-3h-quinolin-7-yl)benzaldehyde Chemical compound C1=C2N(CCC)C(=O)CC(C)(C)C2=CC(C)=C1C1=CC(C=O)=CC=C1N(C)C UDCGOFJVJFTADG-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- XQNVDQZWOBPLQZ-UHFFFAOYSA-N 4-(trifluoromethoxy)benzaldehyde Chemical compound FC(F)(F)OC1=CC=C(C=O)C=C1 XQNVDQZWOBPLQZ-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- DGRGLKZMKWPMOH-UHFFFAOYSA-N 4-methylbenzene-1,2-diamine Chemical compound CC1=CC=C(N)C(N)=C1 DGRGLKZMKWPMOH-UHFFFAOYSA-N 0.000 description 1
- ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical compound OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 description 1
- YJRYNJSRYJEBRJ-UHFFFAOYSA-N 5-[[4-(trifluoromethoxy)-3-(4,4,6-trimethyl-2-oxo-1,3-dihydroquinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC(C(CC(=O)N2)(C)C)=C2C=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O YJRYNJSRYJEBRJ-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 241001249193 Artemisia campestris Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- UZNBICYWIOSDAR-UHFFFAOYSA-N BrC1C(N(C2=CC=C(C=C2C1(C)C)C)C(C)C)=O Chemical compound BrC1C(N(C2=CC=C(C=C2C1(C)C)C)C(C)C)=O UZNBICYWIOSDAR-UHFFFAOYSA-N 0.000 description 1
- KYCAGDDPHAWZAE-UHFFFAOYSA-N BrC1C(N(C2=CC=C(C=C2C1(C)C)C)CCC)=O Chemical compound BrC1C(N(C2=CC=C(C=C2C1(C)C)C)CCC)=O KYCAGDDPHAWZAE-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- DSLJESBRLILXSW-UHFFFAOYSA-N C(C1=CC=CC=C1)N1C(C(C2=CC(=CC=C12)C)(C)C)=O.FC(S(=O)(=O)O)(F)F Chemical compound C(C1=CC=CC=C1)N1C(C(C2=CC(=CC=C12)C)(C)C)=O.FC(S(=O)(=O)O)(F)F DSLJESBRLILXSW-UHFFFAOYSA-N 0.000 description 1
- GXITUSCERRRNDI-UHFFFAOYSA-N C=C(C(N1)=O)SC1=O Chemical compound C=C(C(N1)=O)SC1=O GXITUSCERRRNDI-UHFFFAOYSA-N 0.000 description 1
- ALDXAQBFSDSZJR-UHFFFAOYSA-N C=C(C(N1)=O)SC1=S Chemical compound C=C(C(N1)=O)SC1=S ALDXAQBFSDSZJR-UHFFFAOYSA-N 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- HYDZMARBTYAIMU-UWTATZPHSA-N C[C@H](C(N1)=O)NC1=S Chemical compound C[C@H](C(N1)=O)NC1=S HYDZMARBTYAIMU-UWTATZPHSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 238000006364 Duff aldehyde synthesis reaction Methods 0.000 description 1
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 238000007107 Gatterman reaction Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 208000031942 Late Onset disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 238000007013 Reimer-Tiemann formylation reaction Methods 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- XPIVOYOQXKNYHA-RGDJUOJXSA-N [(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl n-heptylcarbamate Chemical compound CCCCCCCNC(=O)OC[C@H]1O[C@H](OC)[C@H](O)[C@@H](O)[C@@H]1O XPIVOYOQXKNYHA-RGDJUOJXSA-N 0.000 description 1
- ZZWABYQKBLDNHJ-UHFFFAOYSA-N [C]=Cc1ccccc1 Chemical compound [C]=Cc1ccccc1 ZZWABYQKBLDNHJ-UHFFFAOYSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 108010022164 acetyl-LDL Proteins 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical class ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 229910052768 actinide Inorganic materials 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 229940062310 avandia Drugs 0.000 description 1
- ZUDYPQRUOYEARG-UHFFFAOYSA-L barium(2+);dihydroxide;octahydrate Chemical compound O.O.O.O.O.O.O.O.[OH-].[OH-].[Ba+2] ZUDYPQRUOYEARG-UHFFFAOYSA-L 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- UOCJDOLVGGIYIQ-PBFPGSCMSA-N cefatrizine Chemical group S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 UOCJDOLVGGIYIQ-PBFPGSCMSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- QYWDBSSGPAVTJX-UHFFFAOYSA-N ethyl 4-(trifluoromethylsulfonyloxy)quinoline-2-carboxylate Chemical compound C1=CC=CC2=NC(C(=O)OCC)=CC(OS(=O)(=O)C(F)(F)F)=C21 QYWDBSSGPAVTJX-UHFFFAOYSA-N 0.000 description 1
- UACLREXZGKWWIC-UHFFFAOYSA-N ethyl 4-oxo-1h-quinoline-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)OCC)=CC(=O)C2=C1 UACLREXZGKWWIC-UHFFFAOYSA-N 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 125000001905 inorganic group Chemical group 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- OTHBCWKTCXJYAW-UHFFFAOYSA-N n,n-dibenzylformamide Chemical compound C=1C=CC=CC=1CN(C=O)CC1=CC=CC=C1 OTHBCWKTCXJYAW-UHFFFAOYSA-N 0.000 description 1
- FSJPJQTYBADMOU-UHFFFAOYSA-N n-(2-bromo-5-methoxy-4-methylphenyl)-n-[(4-methoxyphenyl)methyl]-2-methylpropanamide Chemical compound C1=CC(OC)=CC=C1CN(C(=O)C(C)C)C1=CC(OC)=C(C)C=C1Br FSJPJQTYBADMOU-UHFFFAOYSA-N 0.000 description 1
- BGBBUAGBYAMODQ-UHFFFAOYSA-N n-(3-hydroxy-4-methylphenyl)-2-methylpropanamide;n-(3-methoxy-4-methylphenyl)-2-methylpropanamide Chemical compound CC(C)C(=O)NC1=CC=C(C)C(O)=C1.COC1=CC(NC(=O)C(C)C)=CC=C1C BGBBUAGBYAMODQ-UHFFFAOYSA-N 0.000 description 1
- ZBGRNWYPTUDFTE-UHFFFAOYSA-N n-(3-methoxy-4-methylphenyl)-2-methylpropanamide Chemical compound COC1=CC(NC(=O)C(C)C)=CC=C1C ZBGRNWYPTUDFTE-UHFFFAOYSA-N 0.000 description 1
- LZHOQSWKKNALGP-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]-2-methylpropanamide Chemical compound COC1=CC=C(CNC(=O)C(C)C)C=C1 LZHOQSWKKNALGP-UHFFFAOYSA-N 0.000 description 1
- ACVHDOLKAPAIGB-UHFFFAOYSA-N n-benzyl-n-methylformamide Chemical compound O=CN(C)CC1=CC=CC=C1 ACVHDOLKAPAIGB-UHFFFAOYSA-N 0.000 description 1
- FJLHLDBEZKTSOK-UHFFFAOYSA-N n-ethyl-n-methylformamide Chemical compound CCN(C)C=O FJLHLDBEZKTSOK-UHFFFAOYSA-N 0.000 description 1
- KERBAAIBDHEFDD-UHFFFAOYSA-N n-ethylformamide Chemical compound CCNC=O KERBAAIBDHEFDD-UHFFFAOYSA-N 0.000 description 1
- KVTGAKFJRLBHLU-UHFFFAOYSA-N n-propan-2-ylformamide Chemical compound CC(C)NC=O KVTGAKFJRLBHLU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- GEVPUGOOGXGPIO-UHFFFAOYSA-N oxalic acid;dihydrate Chemical compound O.O.OC(=O)C(O)=O GEVPUGOOGXGPIO-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 231100000847 severe hepatotoxicity Toxicity 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000005032 thiofuranyl group Chemical group S1C(=CC=C1)* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
本願は、2002年3月8日に出願された米国仮特許出願第60/362,702号に対する優先権を主張しており、その開示内容は、全体が本明細書中で参考として援用されている。
2型糖尿病はまた、インシュリン非依存性糖尿病(NIDDM)とも呼ばれているが、先進国では、全糖尿病患者の80〜90%が罹患している。米国だけでも、約千五百万人、全世界では、1億人を超える人が、罹患している。この疾患は、遅発性疾患であり、しばしば、太り過ぎの人に起こるので、この疾患に罹っている患者の数がさらに増えると予想できる。2型糖尿病に罹った患者は、通常、依然としてインシュリンを産生するが、自身のインシュリンおよびインシュリン療法に対する耐性が増す。
本発明の一部の実施態様は、以下の構造を有する複素環化合物またはそれらの薬学的に受容可能な塩に関する:
a)Ar5は、アリール、置換アリール、ヘテロアリールまたは置換ヘテロアリールである;
b)B、H、I、JおよびKは、別個に、−C(O)−、−C(S)−、−O−、−S−、−N(R101)−、−N(R102)−、−C(R103)(R104)−、−C(R105)(R106)−または−C(R107)(R108)−から選択され、ここで、B、H、I、JまたはKの1個または2個は、必要に応じて、不在であり得る;そして
i)R101、R102、R103、R104、R105、R106、R107およびR108は、別個に、水素、ヒドロキシル、ハロゲン、アミノまたは、または有機ラジカルから選択される;
ii)B、H、I、JおよびKの2個は、以下の構造を有する少なくとも1個のラジカルを形成する:
iii)Ar5は、B、H、I、JおよびKと一緒になって、2個〜24個の炭素原子を含有する;
c)Ar6は、アリール、置換アリール、ヘテロアリールまたは置換ヘテロアリールである;
d)R109は、水素、ヒドロキシまたは有機ラジカルである;
e)−−−−−は、存在するか存在しないかいずれかである;
f)HArは、以下の構造を有する:
本発明は、本発明の種々の実施態様の以下の詳細な説明およびそこに含まれる実施例および図面および先の記述および以下の記述を参照することにより、さらに容易に理解できる。本発明の化合物、組成物および/または方法を開示し記述する前に、本発明は、特定の合成方法、特定の医薬担体または処方物、または本発明の化合物を投与する特定の様式には限定されず、それ自体、もちろん、変えることができることが理解できるはずである。また、本明細書中で使用する専門用語は、特定の実施態様を記述する目的のためのみであり、限定するとは解釈されないことが理解できるはずである。
本明細書およびここに記載された式では、以下の用語は、以下のように定義される。
a)該B、H、I、JおよびK残基は、別個に、−C(O)−、−C(S)−、−O−、−S−、−N(R101)−、−N(R102)−、−C(R103)(R104)−、−C(R105)(R106)−または−C(R107)(R108)−残基から選択され、そして該B、H、I、JまたはK残基の0個〜2個は、不在せあり得る;ここで:
i)R101、R102、R103、R104、R105、R106、R107およびR108は、別個に、水素、ヒドロキシル、ハロゲン、アミノまたは有機残基から選択され、1個〜12個の炭素原子を含有する;またはR101、R102、R103、R104、R105、R106、R107およびR108残基の2個は、共に結合して、環外残基を形成でき、該環外残基は、1個〜6個の環炭素原子および0個〜3個の任意の環ヘテロ原子を含有し、該ヘテロ原子は、O、SまたはNから選択される;そして
ii)B、H、I、JおよびKは、該Ar5と一緒になって、環を形成し、該環は、次式を有する少なくとも1個のアミド残基を含有する:
b)Ar5は、アリール、置換アリール、ヘテロアリールまたは置換ヘテロアリール残基であり、3個〜6個の環炭素原子および0個〜3個の任意の環ヘテロ原子を含有し、該環ヘテロ原子は、O、SまたはNから選択される;
c)Ar6は、アリール、置換アリール、ヘテロアリールまたは置換ヘテロアリール残基であり、2個〜6個の環炭素原子および0個〜3個の任意の環ヘテロ原子を含有し、該環ヘテロ原子は、O、SまたはNから選択される;
d)R109は、水素、ヒドロキシまたは有機残基であり、該有機残基は、1個〜10個の炭素原子を含有する;
e)−−−−−は、存在するか存在しないかいずれかである;
f)W、X、YおよびZは、別個に、または−C(O)−、−C(S)−、−S−、−O−または−NH−と一緒になって、2,4−チアゾリジンジオン、2−チオキソ−チアゾリジン−4−オン、2,4−イミダゾリジンジオンまたは2−チオキソ−イミダゾリジン−4−オン残基である;またはそれらの薬学的に受容可能な塩である。
a)Ar5は、アリール、置換アリール、ヘテロアリールまたは置換ヘテロアリールである;
b)B、H、I、JおよびKは、別個に、−C(O)−、−C(S)−、−O−、−S−、−N(R101)−、−N(R102)−、−C(R103)(R104)−、−C(R105)(R106)−または−C(R107)(R108)−から選択され、ここで、B、H、I、JまたはKの1個または2個は、必要に応じて、不在であり得る;そして
i)R101、R102、R103、R104、R105、R106、R107およびR108は、別個に、水素、ヒドロキシル、ハロゲン、アミノまたは、または有機ラジカルから選択され、該有機ラジカルは、1個〜12個の炭素原子を含有する;
ii)B、H、I、JおよびKの2個は、以下の構造を有する少なくとも1個のラジカルを形成する:
iii)Ar5は、B、H、I、JおよびKと一緒になって、2個〜24個の炭素原子を含有する;
c)Ar6は、アリール、置換アリール、ヘテロアリールまたは置換ヘテロアリールであり、2個〜18個の炭素原子を含有する;
d)R109は、水素、ヒドロキシまたは有機ラジカルであり、該有機ラジカルは、1個〜10個の炭素原子を含有する;
e)−−−−−は、存在するか存在しないかいずれかである;
f)HArは、以下の構造を有する複素環である:
b)Ar6は、以下の構造を有する:
c)−−−−−は、存在するか存在しないかいずれかである;
d)W、X、YおよびZは、一緒になって、以下の構造を有する複素環基を形成する:
本明細書中で開示した化合物を製造する際には、種々の合成方法が使用できる。代表的な合成経路のセットは、Ar5ラジカルおよび結合した非芳香族複素環(これは、アミド基を含む)の前駆体の合成について、図8で示されている。その合成が図8で示されている合成前駆体は、図9で図示した方法により、Ar6とカップリングされ、引き続いて、加工されて、本発明の化合物を提供できる。
a)i)以下の構造を有するAr5前駆体化合物を、
本明細書中で開示された化合物は、純粋な化学物質として投与できるものの、その活性成分を、医薬組成物として提供することが好ましい。それゆえ、他の実施態様は、その1種またはそれ以上の薬学的に受容可能な担体、および必要に応じて、他の治療成分および/または予防成分と共に、1種またはそれ以上の化合物および/またはそれらの薬学的に受容可能な塩を含有する医薬組成物の使用である。これらの担体は、その組成物の他の成分と相溶性であり、それを受ける人に過度に有害ではないという意味で、「受容可能」でなければならない。
本発明の化合物は、インビトロおよびインビボの両方において、ヒトの疾患に相関しているかそれを代表する多数の生物学的アッセイで活性な、強力な化合物であることが発見された。
(図2a〜eおよび実施例27の結果を参照)
3つのマウスモデルのうち、KKAyマウスは、2型糖尿病(高血糖症、高トリグリセリド血症および高コレステロール血症を含めて)の最も重症の症状を示し、従って、しばしば、治療が最も困難である。
(図3および実施例28の結果を参照)
db/dbマウス、ob/obマウスの両方は、2型糖尿病のモデルと見なされているものの、これらのモデルでの疾患の重症度は、KKAyマウスほど顕著ではない。それらは、しかしながら、依然として、これらの化合物で2型糖尿病を治療する際の有効性を立証する手段として、使用されている。図3から容易に分かるように、化合物25は、db/dbマウスにおいて、血清グルコースおよび血清トリグリセリドを同時かつ有益に低下させるのに非常に有効であることが分かった。
(図4および実施例29の結果を参照)
コレステロール値が高いと、アテローム性動脈硬化症および心臓病を引き起こし、これは、多くの2型糖尿病患者では、死亡の原因となる。アテローム硬化型外傷は、コレステロール装填マクロファージ泡沫細胞から生じる[Gownら、(1986)Am.J.Phathol.125,191−207]。インビトロでは、コレステロール装填マクロファージは、細胞培養物中にて、過剰なコレステロールを取り外すことができ、これは、「Cholesterol Efflux Assay」(実施例29を参照)で測定できる。マクロファージ泡沫細胞から放出されたコレステロールは、肝臓により代謝され、そして体内から排出され得る。従って、アテローム硬化型外傷におけるマクロファージからのコレステロール流出を高める新規治療薬は、冠動脈疾患に罹った患者(例えば、肥満および糖尿病の患者)の結果を向上できる。
(図5および実施例30の結果を参照)
化合物が特定の脂質(例えば、コレステロール)を低下させるか善玉コレステロールと悪玉コレステロールとの比(すなわち、HDL対LDL)を変える性能は、動物モデルにおいて測定できる。このような試験のために通例使用される1つの動物モデルは、食餌誘発性の高コレステロール血症野生型SDラットである(実施例30を参照)。
(図6および実施例31の結果を参照)
これらの化合物が抗乳癌剤として機能する性能は、野生型SDラットの発癌物質誘発乳腺癌において、インビボで、立証できる[Thompson H.Jら、Carcinogenesis,13(9),1535−1539(1992)]。
(図7および実施例32の結果を参照)
経口バイオアベイラビリティーは、薬剤開発を進歩させるための、化合物の重要な医薬特性である。化合物の経口バイオアベイラビリティーの基本的な評価は、野生型ラットにおける単一用量の薬物動態学研究で行うことができる。
本明細書中で開示した化合物は、例えば、代謝(例えば、脂質代謝および糖質代謝)または脂肪細胞の分化を変調させるのに有用である。糖質代謝の変化はまた、直接的または間接的に、脂質代謝の変化を生じ得、同様に、脂質代謝の変化は、糖質代謝の変化を引き起こし得る。一例は、2型糖尿病であり、この場合、患者における遊離脂肪酸の増加は、グルコースの細胞摂取および代謝の減少を引き起こす。
a.3−(1,4,4,6−テトラメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−4−トリフルオロメトキシ−ベンズアルデヒド。
a.3−(1−エチル−4,4,6−トリメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−4−トリフルオロメトキシ−ベンズアルデヒド。
a.4−ジメチルアミノ−3−(1,4,4,6−テトラメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−ベンズアルデヒド。
a.4−クロロ−3−(1,4,4,6−テトラメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−ベンズアルデヒド。
a.2−フルオロ−4−メトキシ−3−(1,4,4,6−テトラメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−ベンズアルデヒド。
a.3−(1−プロピル−4,4,6−トリメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−4−トリフルオロメトキシ−ベンズアルデヒド。
a.3−(1−イソプロピル−4,4,6−トリメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−4−トリフルオロメトキシ−ベンズアルデヒド。
ヘキサメチルテトラミン(53.88g、0.384mmol)をTFA(140mL)に慎重に加え、その溶液を80℃まで温めた。その反応混合物に、2,5−ジニトロフェノール(25g、0.192mmol)のTHF(60mL)溶液を滴下し、この反応物を、80℃で、3時間攪拌した。この溶液をトルエンで希釈し、そのTFAを減圧下にて除去した。次いで、この溶液を氷水に注ぎ、そして酢酸エチルで抽出し、水、NaHCO3飽和水溶液(pH=6まで)、水およびブラインで連続的に洗浄し、乾燥し(MgSO4)、濾過し、そして蒸発させて、17gの粗2,5−ジフルオロ−4−ヒドロキシベンズアルデヒドを得、これを、そのまま、次の工程で使用した。
6−メトキシ−1−(4−メトキシ−ベンジル−3,3,5−トリメチル−1,3−ジヒドロ−インドール−2−オン(640mg、1.97mmol)を酢酸(0.7mL)および48%臭化水素酸(7mL)と混合し、そして12時間にわたって、還流状態まで加熱した。その溶液を0℃まで冷却し、そしてNa2CO3水溶液を加えて、pH=7に調節し、次いで、EtOAcで抽出し、ブラインで洗浄し、MgSO4で乾燥し、濾過し、そして減圧下にて蒸発させた。その残留物をシリカゲルカラムクロマトグラフィー(ヘキサン:EtOAc/4:1〜1:1)で精製して、280mgの6−ヒドロキシ−3,3,5−トリメチル−1,3−ジヒドロ−インドール−2−オン(74%)を得た。
N−(2−ブロモ−5−メトキシ−4−メチル−フェニル)−N−(4−メトキシ−ベンジル)−イソブチルアミド(8.72g、21.4mmol)の無水1,4−ジオキサン(80mL)溶液に、ナトリウム第三級ブトキシド(3.09g、32.1mmol)を加えた。約15分間にわたってアルゴンを泡立たせた後、酢酸パラジウム(II)(241mg、1.07mmol)およびトノシクロヘキシルホスフィン(300mg、1.07mmol)を加えた。その混合物を、16時間にわたって、還流状態まで加熱した。この混合物を室温まで冷却し、水で希釈し、そしてEtOAcで抽出し、ブラインで洗浄し、MgSO4で乾燥し、濾過し、そして蒸発させた。その残留物をシリカゲルカラムクロマトグラフィー(ヘキサン:EtOAc/5:1〜3:1)で精製して、5.4gの6−メトキシ−1−(4−メトキシ−ベンジル−3,3,5−トリメチル−1,3−ジヒドロ−インドール−2−オン(77%)を得た。
N−(2−ブロモ−5−メトキシ−4−メチル−フェニル)−イソブチルアミド(6.83g)のDMSO(40mL)溶液に、アルゴン下にて、粉末KOH(2.68g、47.7mmol)および4−メトキシベンジルクロライド(7.5g、47.7mmol)を加えた。その混合物を、室温で、17時間攪拌した。水(30mL)を加え、この混合物をEtOAcで抽出し、ブラインで洗浄し、MgSO4で乾燥し、濾過し、そして減圧下にて蒸発させた。その残留物をシリカゲルカラムクロマトグラフィー(ヘキサン:EtOAc/10:1〜3:1)で精製して、8.72gのN−(2−ブロモ−5−メトキシ−4−メチル−フェニル)−N−(4−メトキシ−ベンジル)−イソブチルアミド(90%)を得た。
N−(3−メトキシ−4−メチル−フェニル)−イソブチルアミド(5.0g、24.1mmol)のジクロロメタン(200mL)溶液に、0℃で、三臭化テトラブチルアンモニウム(12.2g、25.3mmol)を加えた。次いで、その混合物を、室温で、20時間攪拌した。この溶液を、水、ブライン、炭酸水素ナトリウム水溶液、ブラインで洗浄し、MgSO4で乾燥し、濾過し、そして減圧下にて蒸発させて、6.83gのN−(2−ブロモ−5−メトキシ−4−メチル−フェニル)−イソブチルアミド(99%)を得た。
N−(3−ヒドロキシ−4−メチル−フェニル)−イソブチルアミド(6.48g、33.5mmol)をアセトン40mLに溶解し、炭酸カリウム(13.9g、100.5mmol)を加え、続いて、ヨウ化メチル(14.3g、100.5mmol)を加えた。その混合物を、室温で、約3日間攪拌した。その溶液を濾過し、そして減圧下にて蒸発させて、6.6gのN−(3−メトキシ−4−メチル−フェニル)−イソブチルアミド(95%)を得た。
5−アミノ−2−メチルフェノール(30g、244mmol)、10%NaOH(210mL)およびジクロロメタン(120mL)の混合物に、0℃で、ジクロロメタン(50mL)中の塩化イソブチル(25.5mL、244mmol)をゆっくりと加えた。この混合物を、室温で、一晩攪拌した。その水層を分離し、そしてEtOAcで抽出し、ブラインで洗浄し、MgSO4で乾燥し、濾過し、そして減圧下にて蒸発させて、37.2gのN−(3−ヒドロキシ−4−メチル−フェニル)−イソブチルアミド(78%)を得た。
1)KKAyビヒクル対照(ゴマ油)
2)化合物1(3mg/kg)
3)化合物1(10mg/kg)
4)化合物2(3mg/kg)
5)化合物2(10mg/kg)
治療群B(n=6匹/群):(図2bの結果を参照)
1)KKAyビヒクル対照(ゴマ油)
2)化合物11(15mg/kg)
治療群C(n=6匹/群):(図2cの結果を参照)
1)KKAyビヒクル対照(ゴマ油)
2)化合物13(15mg/kg)
治療群D(n=6匹/群):(図2dの結果を参照)
1)KKAyビヒクル対照(CMC)
2)化合物25(3mg/kg、CMC)
化合物25をカルボキシメチルセルロースの溶液(CMC;10%ポリエチレングリコール400と共に、H2O中の1%カルボキシメチルセルロース)に懸濁し、そして5ml/kg/用量の容量で、動物に投与した。
1)KKAyビヒクル対照(10%HPβCD)
2)化合物25(1mg/kg)
3)化合物25(3mg/kg)
4)化合物25(10mg/kg)
化合物25を10%ヒドロキシプロピルベータシクロデキストリン溶液に溶解し、そして10ml/kg/用量の容量で、動物に投与した。
1)db/db対照(CMC)
2)化合物25(0.1mg/kg、CMC中)
3)化合物25(0.3mg/kg、CMC中)
4)化合物25(1mg/kg、CMC中)
化合物25をカルボキシメチルセルロースの溶液(CMC;10%ポリエチレングリコール400と共に、H2O中の1%カルボキシメチルセルロース)に懸濁し、そして5ml/kg/用量の容量で、動物に投与した。この薬剤を、人工光サイクルの開始時にて、毎日1回、経口栄養補給により、投与する。
(培地中の[3H]コレステロール)/(培地中の[3H]コレステロール+細胞中の[3H]コレステロール)×100
図4で示すように、化合物2は、非処理細胞と比較して、THP−1細胞からのコレステロールの流出を高める。
1)痩せた対照(ゴマ油)
2)対照
3)化合物2(0.3mg/kg)
4)化合物2(1mg/kg)
5)化合物2(3mg/kg)
治療群B(n=6匹/群):(図5bの結果を参照)
1)痩せた対照(ゴマ油)
2)対照
3)化合物6(3mg/kg)
治療群C(n=6匹/群):(図5cの結果を参照)
1)痩せた対照(10%HPβCD)
2)対照
3)化合物25(1mg/kg)
4)化合物25(3mg/kg)
5)化合物25(10mg/kg)
6)化合物25(15mg/kg)
これらの化合物を10%ヒドロキシプロピルベータシクロデキストリン溶液に溶解し、そして10mg/kg/用量の容量で、動物に投与した。
1)対照(ゴマ油)
2)化合物6(20mg/kg)
3)化合物11(100mg/kg)
4)化合物13(50mg/kg)
5)化合物24(50mg/kg)
6)化合物25(20mg/kg)
7)化合物25(100mg/kg)
試験した全ての化合物をゴマ油に懸濁し、そして化合物25(これは、10%ヒドロキシプロピルベータシクロデキストリン溶液に溶解した)を10ml/kg/用量の容量で動物に投与したこと以外は、3ml/kg/用量の容量で、動物に投与した。全ての治療は、4週間にわたって、毎日1回、経口栄養補給により、投与した。
6〜8週齡のオスSprague Dawleyラット(Harlan)を一定の12〜12時間人工光−暗黒サイクルに収容し、そして標準的な齧歯類の食餌を適宜与えて維持した。この研究を開始する前に、動物を、2日間、この実験環境に慣らした。化合物24および25を10%ヒドロキシプロピルベータシクロデキストリン溶液に溶解し、そして5ml/kgの容量にて、10ml/kgの最終用量で、投与した。治療群は、以下のように分類した:
治療群(n=3匹/群):
1)化合物24(10mg/kg)
2)化合物25(10mg/kg)
各動物を1回治療し、その後、その動物を、以下の時点で、尾静脈から採血した:治療後、0.5時間、1時間、2時間、4時間、6時間、9時間、12時間および26時間。血漿中の各化合物の濃度を測定するために、ヘパリン被覆チューブにて、血液試料を採取し、その血漿をHPLCで単離し分析した。化合物25は、化合物24と比較して、著しく高い濃度で存在しており、これは、これらの血漿試料での検出限界近くでのみ存在していると検出されたにすぎなかった(図7)。このことは、化合物25が化合物24よりも向上したバイオアベイラビリティーおよび薬剤特性を有することを強調している。
Claims (54)
- 以下の構造を有する化合物、またはそれらの薬学的に受容可能な塩であって:
a)Ar5は、アリール、置換アリール、ヘテロアリールまたは置換ヘテロアリールであり;
b)B、H、I、JおよびKは、独立して、−C(O)−、−C(S)−、−O−、−S−、−N(R101)−、−N(R102)−、−C(R103)(R104)−、−C(R105)(R106)−または−C(R107)(R108)−から選択され、ここで、B、H、I、JまたはKの1個または2個は、必要に応じて、不在であり得;そして
i)R101、R102、R103、R104、R105、R106、R107およびR108は、独立して、水素、ヒドロキシル、ハロゲン、アミノまたは、または有機ラジカルから選択され、該有機ラジカルは、1個〜12個の炭素原子を含有し;
ii)B、H、I、JおよびKの2個は、以下の構造を有する少なくとも1個のラジカルを形成し:
iii)Ar5は、B、H、I、JおよびKと一緒になって、2個〜24個の炭素原子を含有し;
c)Ar6は、アリール、置換アリール、ヘテロアリールまたは置換ヘテロアリールであり、2個〜18個の炭素原子を含有し;
d)R109は、水素、ヒドロキシまたは有機ラジカルであり、該有機ラジカルは、1個〜10個の炭素原子を含有し;
e)−−−−−は、存在するか存在しないかいずれかであり;
f)HArは、以下の構造:
化合物。 - Ar5が、ベンゼン、ピリジン、ピリミジンまたはピラジン環を含む、請求項1に記載の化合物。
- 前記Ar5環が、1個または2個の追加置換基で置換されており、該追加置換基が、ハロゲン、アミノまたはラジカルから独立して選択され、該ラジカルが、1個〜4個の炭素原子を有し、アルキル、一置換アミノ、二置換アミノ、アルコキシまたはハロアルコキシから選択される、請求項2に記載の化合物。
- 前記Ar5が、ベンゼン環であり、該ベンゼン環が、必要に応じて、1個または2個の追加置換基で置換されており、該追加置換基が、ハロゲン、アミノまたはラジカルから独立して選択され、該ラジカルが、1個〜4個の炭素原子を有し、アルキル、一置換アミノ、二置換アミノ、アルコキシまたはハロアルコキシから選択される、請求項1に記載の化合物。
- Bが、存在していない、請求項5に記載の化合物。
- R103およびR104、またはR105およびR106、またはR107およびR108が、共に結合して、環を形成し、該環が、3個〜6個の環炭素原子および0個〜3個の任意の環ヘテロ原子を含有し、該ヘテロ原子が、O、SまたはNから選択される、請求項1に記載の化合物。
- R103およびR104、またはR105およびR106、またはR107およびR108が、共に結合して、シクロアルキルを形成し、該シクロアルキルが、3個〜6個の炭素原子を含有する、請求項1に記載の化合物。
- Ar6が、ベンゼン、ピリジン、ピリミジンまたはピラジン環を含む、請求項1に記載の化合物。
- 前記Ar6環が、さらに、1個、2個または3個の置換基で置換され、該置換基が、独立して、ハロゲンまたはラジカルから選択され、該ラジカルが、1個〜4個の炭素原子を含有し、アルキル、ハロアルキル、アミノ、一置換アミノ、二置換アミノ、アルコキシまたはハロアルコキシから選択される、請求項14に記載の化合物。
- R125が、水素ではない、請求項16に記載の化合物。
- −−−−−が、存在している、請求項19に記載の化合物。
- R109が、水素またはアルキルであり、該アルキルが、1個〜4個の炭素原子を有する、請求項1に記載の化合物。
- R109が、水素である、請求項1に記載の化合物。
- R109が、水素である、請求項8に記載の化合物。
- 前記カチオンが、薬学的に受容可能なカチオンであり、該薬学的に受容可能なカチオンが、アルミニウム、カルシウム、リチウム、マグネシウム、カリウム、ナトリウムまたは亜鉛カチオンの金属カチオン、またはベンザチンを含むアンモニウムカチオン、クロロプロカイン、コリン、ジエタノールアミン、エチレンジアミン、メグルミン、プロカイン、t−ブチルアミン、またはトリス(ヒドロキシメチル)アミノメタンラジカルから選択される、請求項28に記載の化合物。
- 高脂肪食餌を維持したKKAyまたはdb/dbマウスに、約0.3mg/kgの濃度で、7日間にわたって、経口投与したとき、前記化合物を受けなかった対照マウスと比較して、少なくとも約5%だけ、該マウスの血清グルコースレベルを低下させるのに有効である、請求項1に記載の化合物。
- 高脂肪食餌を維持したKKAyまたはdb/dbマウスに、約0.3mg/kgの濃度で、7日間にわたって、経口投与したとき、前記化合物を受けなかった対照マウスと比較して、少なくとも約5%だけ、該マウスの血清トリグリセリドレベルを低下させるのに有効である、請求項1に記載の化合物。
- 約1×10−6Mの濃度で約7日間にわたって適用したとき、約1×10−7Mの濃度でマウスの前脂肪細胞3T3−L1の対照培養物に適用したときに5−[3−(3,5,5,8,8−ペンタメチル−5,6,7,8−テトラヒドロ−ナフタレン−2−イル)−4−トリフルオロメトキシ−ベンジリデン]−チアゾリジン−2,4−ジオンにより誘発される脂肪蓄積の少なくとも約20%だけ培養物の脂肪含量を高めるように、マウスの前脂肪細胞3T3−L1の十分な分化を誘発するのに有効である、請求項1に記載の化合物。
- 哺乳動物において、糖尿病、癌またはアテローム性動脈硬化症を処置する量、または脂質代謝、糖質代謝、脂質および糖質代謝を変調させる量で、1種以上の薬学的に受容可能なキャリアと1種以上の請求項1に記載の化合物またはそれらの薬学的に受容可能な塩とを含有する、薬学的組成物。
- 脂質代謝、糖質代謝、または脂質および糖質代謝を変調させる方法であって、このような変調が必要と診断された哺乳動物に、請求項34に記載の薬学的組成物を投与する工程を包含する、方法。
- 脂質代謝、糖質代謝、または脂質および糖質代謝を変調させる方法であって、このような変調が必要と診断された哺乳動物に、1種以上の請求項1に記載の化合物またはそれらの薬学的に受容可能な塩を投与する工程を包含する、方法。
- 高コレステロール血症を処置する方法であって、このような処置が必要と診断された哺乳動物に、1種以上の請求項1に記載の化合物またはそれらの薬学的に受容可能な塩を投与する工程を包含する、方法。
- 前記1種以上の化合物または塩が、血清コレステロールレベルを少なくとも約5%だけ低下させるのに有効な量で、適用される、請求項36に記載の方法。
- 異脂肪血症を処置する方法であって、このような処置が必要と診断された哺乳動物に、該動物のトリグリセリドレベルを低下させるのに有効な量で、1種以上の請求項1に記載の化合物またはそれらの薬学的に受容可能な塩を投与する工程を包含する、方法。
- 前記1種以上の化合物または塩が、トリグリセリドレベルを少なくとも約5%だけ低下させるのに有効な量で、適用される、請求項38に記載の方法。
- 2型糖尿病を処置する方法であって、このような処置が必要と診断された哺乳動物に、該2型糖尿病を処置するのに有効な量で、1種以上の請求項1に記載の化合物またはそれらの薬学的に受容可能な塩を投与する工程を包含する、方法。
- 前記1種以上の化合物または塩が、血液グルコースレベルを少なくとも約5%だけ低下させるのに有効な量で、適用される、請求項40に記載の方法。
- 2型糖尿病を処置する方法であって、このような処置が必要と診断されたヒトに、血清グルコースレベルを少なくとも約5%だけ低下させ血清トリグリセリドレベルを少なくとも約5%だけ低下させるのに有効な量で、1種以上の請求項1に記載の化合物またはそれらの薬学的に受容可能な塩を投与する工程を包含する、方法。
- 癌を処置する方法であって、このような処置が必要と診断された哺乳動物に、該癌を処置するのに有効な量で、1種以上の請求項1に記載の化合物またはそれらの薬学的に受容可能な塩を投与する工程を包含する、方法。
- 前記癌が、乳癌である、請求項43に記載の方法。
- 請求項1に記載の化合物と塩基とを反応させて薬学的に受容可能な塩を形成する工程をさらに包含する、請求項46に記載の方法。
- 以下の構造を有する化合物、またはそれらの薬学的に受容可能な塩であって:
a)該残基
b)Ar6は、以下の構造を有し:
c)−−−−−は、存在するか存在しないかいずれかであり;
d)W、X、YおよびZは、一緒になって、以下の構造を有する複素環:
- 式(200)の化合物、またはそれらの薬学的に受容可能な塩であって:
a)該B、H、I、JおよびK残基は、独立して、−C(O)−、−C(S)−、−O−、−S−、−N(R101)−、−N(R102)−、−C(R103)(R104)−、−C(R105)(R106)−または−C(R107)(R108)−残基から選択され、そして該B、H、I、JまたはK残基の0個〜2個は、存在し得ず;ここで:
i)R101、R102、R103、R104、R105、R106、R107およびR108は、独立して、水素、ヒドロキシル、ハロゲン、アミノまたは有機残基から選択され、1個〜12個の炭素原子を含有するか;またはR101、R102、R103、R104、R105、R106、R107およびR108残基の2個は、共に結合して、環外残基を形成し得、該環外残基は、1個〜6個の環炭素原子および0個〜3個の任意の環ヘテロ原子を含有し、該ヘテロ原子は、O、SまたはNから選択され;そして
ii)B、H、I、JおよびKは、該Ar5と一緒になって、環を形成し、該環は、次式を有する少なくとも1個のアミド残基を含有し:
b)Ar5は、アリール、置換アリール、ヘテロアリールまたは置換ヘテロアリール残基であり、3個〜6個の環炭素原子および0個〜3個の任意の環ヘテロ原子を含有し、該環ヘテロ原子は、O、SまたはNから選択され;
c)Ar6は、アリール、置換アリール、ヘテロアリールまたは置換ヘテロアリール残基であり、2個〜6個の環炭素原子および0個〜3個の任意の環ヘテロ原子を含有し、該環ヘテロ原子は、O、SまたはNから選択され;
d)R109は、水素、ヒドロキシまたは有機残基であり、該有機残基は、1個〜10個の炭素原子を含有し;
e)−−−−−は、存在するか存在しないかいずれかであり;
f)W、X、YおよびZは、独立して、または−C(O)−、−C(S)−、−S−、−O−または−NH−と一緒になって、2,4−チアゾリジンジオン、2−チオキソ−チアゾリジン−4−オン、2,4−イミダゾリジンジオンまたは2−チオキソ−イミダゾリジン−4−オン残基である、
化合物。 - 次式を有する化合物、またはそれらの薬学的に受容可能な塩:
5−[3−(1−エチル−4,4,6−トリメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−4−トリフルオロメトキシ−ベンジリデン]−チアゾリジン−2,4−ジオン。 - 次式を有する化合物、またはそれらの薬学的に受容可能な塩:
5−[3−(1,4,4,6−テトラメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−4−トリフルオロメトキシ−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−[4−ジメチルアミノ−3−(1,4,4,6−テトラメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−[4−ジメチルアミノ−3−(1−エチル−4,4,6−トリメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−[3−(1,4,4,6−テトラメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−4−クロロ−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−[3−(1−エチル−4,4,6−トリメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−4−クロロ−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−[2−フルオロ−4−メトキシ−3−(1,4,4,6−テトラメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−[3−(1−プロピル−4,4,6−トリメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−4−トリフルオロメトキシ−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−[4−ジメチルアミノ−3−(1−プロピル−4,4,6−トリメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−[3−(1−エチル−4,4,6−トリメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−2−フルオロ−4−メトキシ−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−[3−(1−イソプロピル−4,4,6−トリメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−4−トリフルオロメトキシ−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−[4−ジメチルアミノ−3−(1−イソプロピル−4,4,6−トリメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−[3−(1−エチル−4,4,6−トリメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−2,5−ジフルオロ−4−メトキシ−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−[4−エチルアミノ−3−(1−エチル−4,4,6−トリメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−ベンジリデン]−チアゾリジン−2,4−ジオン、
6−[2−ジメチルアミノ−5−(2,4−ジオキソ−チアゾリジン−5−イリデンメチル)−フェニル]−1,4,7−トリメチル−1,4−ジヒドロ−キノキサリン−2,3−ジオン、
5−[3−(1−ベンジル−3,3,5−トリメチル−2−オキソ−2,3−ジヒドロ−1H−インドール−6−イル)−4−トリフルオロメトキシ−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−[3−(1−エチル−4,4,6−トリメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−5−フルオロ−4−メトキシ−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−(1’−エチル−4’,4’,6’−トリメチル−2’−オキソ−1’,2’,3’,4’−テトラヒドロ−[4,7’]ビキノリニル−2−イルメチレン)−チアゾリジン−2,4−ジオン、
5−[2,5−ジフルオロ−4−メトキシ−3−(1,4,4,6−テトラメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−[4−トリフルオロメトキシ−3−(4,4,6−トリメチル−2−オキソ−1,2,3,4−テトラヒドロ−キノリン−7−イル)−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−[3−(1−エチル−3,3,5−トリメチル−2−オキソ−2,3−ジヒドロ−1H−インドール−6−イル)−4−トリフルオロメトキシ−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−[4−トリフルオロメトキシ−3−(3,3,5−トリメチル−2−オキソ−2,3−ジヒドロ−1H−インドール−6−イル)−ベンジリデン]−チアゾリジン−2,4−ジオン、
5−[4−トリフルオロメトキシ−3−(3,3,5−トリメチル−2−オキソ−1−プロピル−2,3−ジヒドロ−1H−インドール−6−イル)−ベンジリデン]−チアゾリジン−2,4−ジオン。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36270202P | 2002-03-08 | 2002-03-08 | |
PCT/US2003/006784 WO2003075924A1 (en) | 2002-03-08 | 2003-03-07 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005530705A true JP2005530705A (ja) | 2005-10-13 |
JP2005530705A5 JP2005530705A5 (ja) | 2006-02-23 |
Family
ID=27805215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003574198A Pending JP2005530705A (ja) | 2002-03-08 | 2003-03-07 | 糖尿病および他の疾患を治療するための複素環アミド誘導体 |
Country Status (14)
Country | Link |
---|---|
US (2) | US7102000B2 (ja) |
EP (1) | EP1487443A4 (ja) |
JP (1) | JP2005530705A (ja) |
KR (1) | KR20050006126A (ja) |
CN (1) | CN1649586A (ja) |
AU (1) | AU2003225682A1 (ja) |
CA (1) | CA2478342A1 (ja) |
IL (1) | IL163952A0 (ja) |
MX (1) | MXPA04008733A (ja) |
NO (1) | NO20044250L (ja) |
RU (1) | RU2004129752A (ja) |
TW (1) | TW200306184A (ja) |
WO (1) | WO2003075924A1 (ja) |
ZA (1) | ZA200408057B (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2383347A1 (en) * | 1999-08-31 | 2001-03-08 | Maxia Pharmaceuticals, Inc. | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes |
BR0207846A (pt) * | 2001-03-07 | 2005-09-13 | Incyte San Diego Inc | Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas |
JP2004523571A (ja) * | 2001-03-08 | 2004-08-05 | マキシア・ファーマシューティカルズ・インコーポレイテッド | Rxr活性化分子 |
US20030083357A1 (en) * | 2001-08-17 | 2003-05-01 | Magnus Pfahl | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia |
US7196108B2 (en) * | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
RU2005135850A (ru) * | 2003-04-18 | 2006-06-10 | Инсайт Сан Диего Инкорпорейтед (Us) | Замещенные изохромановые соединения для лечения метаболических расстройств, рака и другие заболеваний |
EP1566202A1 (en) * | 2004-02-23 | 2005-08-24 | Sahltech I Göteborg AB | Use of resistin antagonists in the treatment of rheumatoid arthritis |
US7122700B2 (en) | 2004-07-30 | 2006-10-17 | Xerox Corporation | Arylamine processes |
GT200500185A (es) * | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
EP1788390B1 (en) * | 2004-08-30 | 2010-04-14 | Takeda Pharmaceutical Company Limited | Screening method |
JP2009512637A (ja) | 2005-09-30 | 2009-03-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 異常脂血症、高コレステロール血症及び糖尿病の処置のためのrxrアゴニストとしてのジヒドロ−[1h]−キノリン−2−オン誘導体 |
WO2009143041A1 (en) | 2008-05-20 | 2009-11-26 | Merck & Co., Inc. | Efficient production of heterologous proteins using mannosyl transferase inhibitors |
US9056862B2 (en) | 2011-05-10 | 2015-06-16 | National University Corporation Kobe University | Thioxothiazolidine derivative having Ras function inhibitory effect |
EP3062819B1 (en) | 2013-11-03 | 2021-12-22 | The Regents of The University of California | Ionic liquids for transdermal drug delivery |
JP6632720B2 (ja) * | 2016-06-07 | 2020-01-22 | 三菱電機株式会社 | 温度推定方法 |
EP3503927A1 (en) | 2016-08-29 | 2019-07-03 | The Regents of the University of California | Topical formulations based on ionic species for skin treatment |
US10828265B2 (en) | 2016-12-09 | 2020-11-10 | The Regents Of The University Of California | Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4051842A (en) * | 1975-09-15 | 1977-10-04 | International Medical Corporation | Electrode and interfacing pad for electrical physiological systems |
DE2626348C3 (de) * | 1976-06-11 | 1980-01-31 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantierbare Dosiereinrichtung |
JPS5538359A (en) | 1978-09-12 | 1980-03-17 | Hamari Yakuhin Kogyo Kk | Preparation of 2-(3-benzoylphenyl)-propionic acid |
US4383529A (en) * | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
IL72684A (en) * | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
US4931279A (en) * | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
US4713244A (en) * | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
US4668506A (en) * | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
CA1325222C (en) | 1985-08-23 | 1993-12-14 | Lederle (Japan), Ltd. | Process for producing 4-biphenylylacetic acid |
JP2539504B2 (ja) * | 1987-03-11 | 1996-10-02 | 鐘淵化学工業株式会社 | ヒドロキシスチレン誘導体 |
FI91869C (fi) * | 1987-03-18 | 1994-08-25 | Tanabe Seiyaku Co | Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi |
JPS63230689A (ja) * | 1987-03-18 | 1988-09-27 | Tanabe Seiyaku Co Ltd | ベンゾオキサジン誘導体 |
US5223522A (en) * | 1988-03-08 | 1993-06-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
US5330998A (en) * | 1988-03-08 | 1994-07-19 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
IE940525L (en) | 1988-05-25 | 1989-11-25 | Warner Lambert Co | Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents |
DK0595868T3 (da) * | 1991-07-22 | 1999-08-09 | Pfizer | Fremgangsmåde til fremstilling af (S)-4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-hydroxypropyl]-brombenzen |
US5780676A (en) * | 1992-04-22 | 1998-07-14 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
PT637297E (pt) | 1992-04-22 | 2001-01-31 | Ligand Pharm Inc | Compostos com selectividade para os receptores de retinoide x |
EP0915090A1 (en) * | 1992-09-10 | 1999-05-12 | Eli Lilly And Company | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease |
BR9307528A (pt) | 1992-11-25 | 1999-08-31 | Jolla Cancer Research Foudatio | Processo para inspecionar subst‰ncia quanto à capacidade de afetar a formação de homodìmero em receptor de retinóide x, processo para inspecionar subst‰ncia quanto à capacidade de induzir seletivamente a formação de heterodìmero em receptor de retinóide x, processo para inspecionar subst‰ncia quanto à capacidade de afetar a capacidade de um homodìmero, em um receptor de retinóide x, se ligar ao dna, processo para inspecionar um elemento de resposta quanto à capacidade de se ligar a um homodìmero em receptor de retinóide x, homodìmero em receptor de retinóide x, composto aromático bicìclico, processo para inibir atividade de heterodìmero em receptor de retinóide x, processo para promover transcrição de um gene ativado por homodìmero em receptor de retinóide em uma célula, processo para inibir atividade de homodìmero em receptor de retinóide x, processo para determinar maior probabilidade de patologia, processo para tratar patologia, processo para ativar seletivamente formação de homodìmero em receptor de retinóide x em uma célula, processo para promover a formação de homodìmero em receptor de retinóide x em uma célula, composição farmacêutica, processo para modular expressão de gene, e processo para tratar paciente |
DE4317320A1 (de) * | 1993-05-25 | 1994-12-01 | Boehringer Mannheim Gmbh | Neue Thiazolidindione und diese enthaltende Arzneimittel |
EP0745063B1 (en) * | 1994-02-17 | 1999-03-24 | American Home Products Corporation | Substituted biphenyl derivatives as phosphodiesterase inhibitors |
US5691376A (en) * | 1994-02-17 | 1997-11-25 | American Home Products Corporation | Substituted biphenyl derivatives |
JPH09136877A (ja) | 1995-06-16 | 1997-05-27 | Takeda Chem Ind Ltd | 複素環化合物、その製造法及び用途 |
JP2000506489A (ja) | 1995-07-17 | 2000-05-30 | センタ インタナショナル ドゥ リシェルシェ デルマトロジーク セ イ エール デ ガルデルマ | Ahpnを用いる癌の治療方法 |
JPH09176162A (ja) * | 1995-12-22 | 1997-07-08 | Toubishi Yakuhin Kogyo Kk | チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物 |
CN1196730A (zh) | 1996-06-19 | 1998-10-21 | 雷迪博士研究基金会 | 具有增强的抗糖尿病活性的穴糖酮的新的多晶型形式及其制备方法 |
RU2209626C2 (ru) * | 1996-07-08 | 2003-08-10 | Галдерма Ресерч энд Девелопмент, С.Н.С. | Производные адамантила, вызывающие апоптоз, и их использование в качестве противораковых агентов |
WO1999009965A2 (en) | 1997-08-21 | 1999-03-04 | Takeda Chemical Industries, Ltd. | Anti-inflammatory agent |
CA2309331A1 (en) | 1997-11-12 | 1999-05-20 | Institute Of Medicinal Molecular Design, Inc. | Agent acting on retinoid receptor |
US6262044B1 (en) * | 1998-03-12 | 2001-07-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPASES) |
US6331633B1 (en) | 1998-05-08 | 2001-12-18 | Calyx Therapeutics Inc. | Heterocyclic analogs of diphenylethylene compounds |
EP1128832A4 (en) | 1998-08-21 | 2003-03-05 | Viropharma Inc | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND RELATED DISEASES |
AU6330999A (en) | 1998-09-30 | 2000-04-17 | Roche Diagnostics Gmbh | Rhodanine derivatives for the treatment and prevention of metabolic bone disorders |
AU3111700A (en) | 1998-12-04 | 2000-06-19 | Structural Bioinformatics Inc. | Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity |
AU3958200A (en) | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
CA2383347A1 (en) * | 1999-08-31 | 2001-03-08 | Maxia Pharmaceuticals, Inc. | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes |
PT1142885E (pt) | 1999-11-12 | 2007-02-28 | Fujimoto Brothers Co Ltd | Derivados de 2-(n-cianoimino)tiazolidin-4-ona |
FR2812876B1 (fr) * | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
BR0207846A (pt) | 2001-03-07 | 2005-09-13 | Incyte San Diego Inc | Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas |
JP2004523571A (ja) | 2001-03-08 | 2004-08-05 | マキシア・ファーマシューティカルズ・インコーポレイテッド | Rxr活性化分子 |
DE60204674T2 (de) | 2001-03-14 | 2006-05-18 | Eli Lilly And Co., Indianapolis | Retinoid x rezeptormodulatoren |
DE60233655D1 (de) | 2001-04-04 | 2009-10-22 | Ortho Mcneil Janssen Pharm | R und retinoid x rezeptorenmodulatoren |
US20030083357A1 (en) * | 2001-08-17 | 2003-05-01 | Magnus Pfahl | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia |
AU2002352706A1 (en) * | 2001-11-15 | 2003-06-10 | Maxia Pharmaceuticals, Inc. | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases |
TW200304375A (en) * | 2001-12-06 | 2003-10-01 | Maxia Pharmaceuticals Inc | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer |
US7196108B2 (en) * | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
WO2004066952A2 (en) * | 2003-01-29 | 2004-08-12 | Incyte Corporation | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases |
RU2005135850A (ru) * | 2003-04-18 | 2006-06-10 | Инсайт Сан Диего Инкорпорейтед (Us) | Замещенные изохромановые соединения для лечения метаболических расстройств, рака и другие заболеваний |
-
2003
- 2003-03-06 US US10/384,352 patent/US7102000B2/en not_active Expired - Fee Related
- 2003-03-07 CN CNA038101483A patent/CN1649586A/zh active Pending
- 2003-03-07 AU AU2003225682A patent/AU2003225682A1/en not_active Abandoned
- 2003-03-07 TW TW092105025A patent/TW200306184A/zh unknown
- 2003-03-07 MX MXPA04008733A patent/MXPA04008733A/es unknown
- 2003-03-07 IL IL16395203A patent/IL163952A0/xx unknown
- 2003-03-07 ZA ZA200408057A patent/ZA200408057B/en unknown
- 2003-03-07 EP EP03744197A patent/EP1487443A4/en not_active Withdrawn
- 2003-03-07 WO PCT/US2003/006784 patent/WO2003075924A1/en active Application Filing
- 2003-03-07 RU RU2004129752/04A patent/RU2004129752A/ru not_active Application Discontinuation
- 2003-03-07 CA CA002478342A patent/CA2478342A1/en not_active Abandoned
- 2003-03-07 JP JP2003574198A patent/JP2005530705A/ja active Pending
- 2003-03-07 KR KR10-2004-7014099A patent/KR20050006126A/ko not_active Application Discontinuation
-
2004
- 2004-10-07 NO NO20044250A patent/NO20044250L/no unknown
-
2006
- 2006-06-28 US US11/476,330 patent/US20060241138A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20060241138A1 (en) | 2006-10-26 |
AU2003225682A1 (en) | 2003-09-22 |
US20030216432A1 (en) | 2003-11-20 |
MXPA04008733A (es) | 2006-07-03 |
CA2478342A1 (en) | 2003-09-18 |
KR20050006126A (ko) | 2005-01-15 |
TW200306184A (en) | 2003-11-16 |
WO2003075924A1 (en) | 2003-09-18 |
EP1487443A1 (en) | 2004-12-22 |
RU2004129752A (ru) | 2005-05-10 |
AU2003225682A2 (en) | 2003-09-22 |
EP1487443A4 (en) | 2006-04-12 |
IL163952A0 (en) | 2005-12-18 |
US7102000B2 (en) | 2006-09-05 |
CN1649586A (zh) | 2005-08-03 |
ZA200408057B (en) | 2007-05-30 |
NO20044250L (no) | 2004-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060241138A1 (en) | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | |
US6765013B2 (en) | Thiazolidinedione derivatives for the treatment of diabetes and other diseases | |
US7196108B2 (en) | Bicyclic heterocycles for the treatment of diabetes and other diseases | |
KR100518142B1 (ko) | 혈당저하 및 지질혈저하 활성을 갖는 5-원n-헤테로고리형 화합물 | |
US20030144329A1 (en) | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | |
AU2006252629A1 (en) | Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases | |
JP2006523724A (ja) | 代謝障害、癌および他の疾患の治療のための置換イソクロマン化合物 | |
EP1593677A2 (en) | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051228 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060227 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090701 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090708 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091201 |